Dana-Farber Reports Metabolically Activated Molecular Glue and New Discovery Platform
Glutathionylation turns a compound into a switch that redirects an understudied E3 ligase to destroy cancer-linked proteins in a proof‑of‑principle study.
Overview
- Dana-Farber researchers published a Nature paper this Friday describing a scalable, E3‑focused screening platform that finds small molecules that join E3 ubiquitin ligases to cellular proteins for targeted degradation.
- The team traced a screening hit to a compound called M12 and used cryo‑EM to show M12 becomes active only after glutathionylation, a metabolic modification tied to oxidative stress.
- Activated M12 engages the understudied E3 ligase DCAF11 to recruit and degrade the protein DDX18 and was tuned in cells to target other cancer‑relevant proteins including SMARCA2, WEE1 and CDK7.
- The glutathionylation requirement implies metabolic state could make molecular glues context dependent and potentially spare normal cells by activating only in oxidative tumor environments.
- Authors emphasize the work is proof‑of‑principle and preclinical; further optimization, specificity testing and safety studies are needed before any candidate can move toward drug development.